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Abstract: A nanoparticle (NP) formulation with 2′-(2-bromohexadecanoyl)-paclitaxel 
(Br-16-PX) conjugate was developed in these studies for the treatment of non-small cell lung can-
cer (NSCLC). The lipophilic paclitaxel conjugate Br-C16-PX was synthesized and incorporated 
into lipid NPs where the 16-carbon chain enhanced drug entrapment in the drug delivery system 
and improved in vivo pharmacokinetics. The electron-withdrawing bromine group was used to 
facilitate the conversion of Br-C16-PX to paclitaxel at the tumor site. The developed system 
was evaluated in luciferase-expressing A549 cells in vitro and in an orthotopic NSCLC mouse 
model. The results demonstrated that the Br-C16-PX NPs had a higher maximum tolerated dose 
(75 mg/kg) than Taxol® (19 mg/kg) and provided significantly longer median survival (88 days 
versus 70 days, P0.05) in the orthotopic NSCLC model. An improved pharmacokinetic profile 
was observed for the Br-C16-PX NPs at 75 mg/kg compared to Taxol at 19 mg/kg. The area under 
the concentration versus time curve (AUC)
0–96 h 
of Br-C16-PX from the NPs was 91.7-fold and 
49.6-fold greater than Taxol in plasma and tumor-bearing lungs, respectively, which provided 
sustained drug exposure and higher antitumor efficacy in the NP-treated group.
Keywords: tubulin polymerization, pharmacokinetic, maximum tolerated dose, efficacy, pleural 
fluid, bioluminescence imaging, A549 cell tumor model
Introduction
Lung cancer is the leading cause of cancer mortality worldwide. An estimated 
224,210 new cases and 159,260 deaths due to lung cancer are expected in 2014, 
accounting for 14% of cancer diagnoses and 27% of all cancer deaths, respectively.1 
Among all lung cancer cases, 84% are classified as non-small cell lung cancer (NSCLC) 
and 15% as small-cell lung cancer for the purpose of treatment. The microtubule 
stabilization agent paclitaxel (PX) is used either as a monotherapy or in combination 
with carboplatin for the treatment of NSCLC.2
Currently PX is commercially marketed as Taxol® (Bristol-Myers Squibb, New York 
City, USA) and Abraxane® (Celgene, Basking Ridge, USA). Taxol contains Cremophor 
EL and dehydrated ethanol as co-solvents to solubilize PX and was given approval 
by the US Food and Drug Administration (FDA) in 1992. However, the hydrophobic 
nature of PX requires the amount of co-solvent to be so high that serious side effects 
including anaphylaxis and severe hypersensitivity are unavoidable. Abraxane, an 
albumin-bound PX nanoparticle (mean diameter 130 nm), was approved by the FDA 
in October 2012 for the first-line treatment of NSCLC in combination with carboplatin. 
In the phase III trial CA-031, weekly albumin-bound paclitaxel (nab-PX) exhibited 
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decreased neuropathy and neutropenia compared to solvent-
based paclitaxel (sb-PX), likely due to the absence of toxic 
excipients.3 However, the 10% improvement of progression-
free survival (P=0.21) and overall survival (P=0.27) was not 
statistically significant. Moreover, the half-life (P=0.48) and 
area under the concentration versus time curve (AUC, P=0.52) 
of Abraxane at 260 mg/m2 were not significantly increased 
compared to Taxol at 175 mg/m2.4 Therefore, a PX formula-
tion with decreased toxicity, improved therapeutic index, and 
better pharmacokinetic (PK) properties is needed.
Nano-formulations of PX have been investigated for 
safer and more effective chemotherapy.5–8 Due to moder-
ate drug solubility or rapid drug release of most PX nano-
formulations, lipophilic PX conjugates or derivatives have 
been developed to increase the stability in hydrophobic 
carrier systems. Previously Ali et al synthesized a series of 
lipophilic PX conjugates bearing 6, 8, 12, 14, or 16-carbon 
chains at the 2′-position.9 The PX conjugate with a long 
16-carbon chain exhibited decreased cytotoxicity compared 
to conjugates with shorter chain lengths, but was therapeuti-
cally more efficacious when loaded into liposomes for the 
treatment of mouse ovarian cancer. Moreover, the incor-
poration of an electron-withdrawing bromine (Br) atom 
was evaluated in the PX conjugates. The bromoacyl PX 
conjugates were 50 to 250-fold more cytotoxic than their 
counterparts without Br in the human MCF-7 breast carci-
noma cell line, indicating Br-induced hydrolysis. However, 
the liposomal formulation with PX conjugate had a rela-
tively low molar ratio of bromoacyl taxane and a broad size 
range between 90 nm and 140 nm. Furthermore, the in vivo 
behavior of the system was not further investigated except 
for survival analysis.
In the current studies, the 2′-(2-bromohexadecanoyl)-
paclitaxel (Br-C16-PX) conjugate was synthesized and 
incoporated into lipid-based NPs for the treatment of NSCLC. 
The 16-carbon chain helps to increase drug entrapment 
and stability in the NPs, and the electron-withdrawing Br 
group at the 2-position of the fatty acid chain enables faster 
hydrolysis to release PX. Tubulin polymerization activity 
and cytotoxicity of the conjugate was investigated. In vivo 
performance of the Br-C16-PX NPs was evaluated in an 
orthotopic NSCLC mouse model previously established and 
characterized in our laboratory.10 Lung cancer survival is 
largely related to cancer stage at the time of diagnosis.11 To 
mimic the therapy of advanced NSCLC, the treatment in 
the current studies was started later than 50% of the median 
survival. The Br-C16-PX NPs were shown to have superior 
therapeutic efficacy and improved PK properties compared 
to Taxol in the orthotopic xenograft model.
Materials and methods
Materials
Polyoxyl 20-stearyl ether (Brij 78) was purchased from 
Uniqema (Wilmington, DE, USA). D-alpha-tocopheryl 
polyethylene glycol-1000 succinate (Vitamin E-TPGS) 
was purchased from Eastman Chemicals (Kingsport, TN, 
USA). Miglyol 812 was purchased from Sasol (Witten, 
Germany). PX powder was bought from LC Laboratories 
(Woburn, MA, USA). Taxol was purchased from Hospira 
Inc. (Lake Forest, IL, USA). Sodium fluoride, 2-bromo-
hexadecanoic acid and 4-dimethylaminopyridine (DMAP) 
were purchased from Sigma-Aldrich Co. (St Louis, MO, 
USA). Sepharose CL-4B was acquired from GE Healthcare 
Life Sciences (Uppsala, Sweden). The tubulin polymer-
ization assay kit was purchased from Cytoskeleton Inc. 
(Denver, CO, USA). D-luciferin potassium salt, A549-
luc-c8 cell line and Caliper IVIS Lumina II were from 
Caliper (Hopkinton, MA, USA). Roswell Park Memorial 
Institute (RPMI) 1640 medium and Dulbecco’s phosphate-
buffered saline (DPBS) were purchased from Thermo 
Fisher Scientific (Waltham, MA, USA). Fetal bovine 
serum (FBS) was purchased from ATCC (Manassas, VA, 
USA). Matrigel was obtained from BD Biosciences (San 
Jose, CA, USA).
Optimization and characterization  
of Br-c16-PX NPs
Br-C16-PX was synthesized as previously reported.9 
Briefly, PX was conjugated with 2-bromohexadecanoic acid 
via a one-step esterification reaction with DMAP (Sigma-
Aldrich Co.) as the catalyst. The product was purified by 
preparative thin layer chromatography. The structure and 
molecular mass were confirmed by nuclear magnetic reso-
nance (NMR) and mass spectrometry.9
Our laboratory has previously prepared PX BTM NPs from 
a warm oil-in-water microemulsion precursor with Brij 78 and 
Vitamin E-TPGS as surfactants and  Miglyol 812 as the oil 
phase (abbreviated as “BTM” NPs).12,13 For the current formu-
lation with Br-C16-PX, the system was optimized by decreas-
ing the amount of surfactants while enhancing drug loading 
and drug entrapment. The particle diameter of the NPs was 
measured using a Coulter N5 Plus Submicron Particle Sizer 
(Beckman Coulter, FL, USA). The drug entrapment efficiency 
was determined by gel permeation chromatography (GPC) 
with Sepharose CL-4B. Briefly, the NPs were loaded onto a 
15 cm GPC column, and fifteen fractions were collected (1 mL 
per fraction) with PBS as the eluent. Light scattering intensity 
of each fraction was determined with the Beckman Coulter N5 
Submicron Particle Size Analyzer. Br-C16-PX concentration 
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was determined by High  Performance  Liquid Chromatog-
raphy (HPLC) (γ=230 nm) with an Inertsil ODS-3 column 
(4.6×150 mm, 4 µm particle size, GL Sciences Inc., Torrance, 
CA, USA) and a mobile phase consisting of acetonitrile/water/
isopropanol (55:10:35, v/v/v) with a flow rate of 1 mL/min.
For in vivo studies in nude mice, the Br-C16-PX NPs were 
pegylated by adding 0.2 mg/mL Brij 700 (Uniqema) during 
the preparation.
Tubulin polymerization activity  
of Br-c16-PX
Tubulin polymerization activity of Br-C16-PX was evaluated 
using a tubulin polymerization assay kit. The standard (con-
trol) polymerization condition includes 3 mg/mL tubulin in 
80 mM piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES) 
buffer at pH 6.9 in the presence of glycerol. PX at 10 µM 
was used as the positive control, and Br-C16-PX was evalu-
ated at 10 µM and 34 µM. The polymerization reaction was 
conducted at 37°C and the degree of tubulin polymerization 
was quantified by the change in absorbance at 340 nm. The 
OD
340 nm
 (optical density) was monitored with a Synergy 
2 Multi-Detection Microplate Reader (BioTek, Winooski, VT, 
USA) over a 60 minute period with one reading per minute. 
The maximum rate of tubulin polymerization (V
max
, mOD/
min) was plotted for the control, and the PX at 10 µM, Br-
C16-PX at 10 µM, and Br-C16-PX at 34 µM groups.
cell culture
Luciferase-expressing human lung adenocarcinoma cell line 
A549-luc-c8 was maintained in RPMI 1640 supplemented 
with 10% FBS and antibiotic. Cells were cultured in a 




The cytotoxicity of Br-C16-PX in A549-luc-c8 human 
lung adenocarcinoma cells was determined using a 3-(4, 
5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay and compared to PX. Briefly, A549-luc-c8 cells 
were cultured as described above and seeded in a 96-well 
plate with 5,000 cells/100 µL growth medium per well. PX, 
Br-C16-PX NPs, or blank NPs without Br-C16-PX were 
added to the plate at a series of different concentrations. 
After 48-hour incubation at 37°C, the cells were incubated 
with MTT solution for another 3 hours. Lastly, dimethyl 
sulfoxide (DMSO) was added to solubilize the converted dye, 
and the absorbance at 570 nm was measured with a Synergy 
2 Multi-Detection Microplate Reader (BioTek). The IC
50
 of 
the drug (the concentration that leads to 50% cell survival 
inhibition) was determined from survival plots.
Orthotopic lung tumor implantation
Four to six week old female nude mice (Harlan Sprague  Dawley) 
were housed in a pathogen-free room. Orthotopic lung tumors 
were established as previously reported.10 Briefly, after mice 
were anesthetized, a 5 mm incision was made on the dorsal side 
over the left lung. Fat and muscles were separated to visualize 
lung movement. Five million A549-luc-c8 cells suspended in 
40 µL PBS/matrigel were injected directly into the left lung 
parenchyma at the depth of 3 mm. All mouse studies were con-
ducted according to a protocol approved by the University of 
North Carolina Institutional Animal Care and Use Committee.
Whole-body bioluminescence imaging
Weekly whole-body bioluminescence imaging was per-
formed in mouse studies to monitor orthotopic lung tumor 
growth. D-luciferin potassium salt reconstituted in DPBS was 
injected intraperitoneally at 150 mg/kg. Mice were anesthe-
tized with 2% isoflurane and imaged by Caliper IVIS Lumina 
II (Caliper) 15 minutes after luciferin injection.
In vivo antitumor efficacy studies
A549-luc-c8 cells were implanted into the left lung of nude 
mice on day 0 as described above. Mice were randomized into 
four groups (9 mice/group): control group (untreated), Taxol 
at 19 mg/kg (established maximum tolerated dose [MTD]), 
Br-C16-PX NPs at 60 mg/kg (“NP 60 group”), and Br-C16-PX 
NPs at 75 mg/kg (“NP 75 group”). Treatments were started 
as intravenous (IV) injections on day 16 with the treatment 
schedule of Q7d ×6. Mice were sacrificed when Body Condi-
tion Scoring (BCS) was 2 or less, or when a total weight loss of 
20% was reached at any time for any mouse in the study.14
histology staining
The efficacy study was terminated on day 154 post tumor 
cell implantation, with one mouse living in the NP 60 group 
and two mice living in the NP 75 group. Lungs of the surviv-
ing mice were harvested. After formalin fixing and paraffin 
embedding, hematoxylin and eosin staining was performed 
for 4 µm sections of the lungs. Histological staining was per-
formed by the Animal Histopathology Core at UNC-Chapel 
Hill. Microscopic observations were carried out with Olympus 
Bx-61 (Olympus Corporation, Tokyo, Japan) in Microscopy 
Services Laboratory at UNC-Chapel Hill.
Quantification of PX and Br-C16-PX by 
liquid chromatography Tandem Mass 
spectrometry (lc-Ms/Ms)
PX, Br-C16-PX and docetaxel (internal standard) were 
separated on a Waters XSelect CSH Phenyl-Hexyl column 





(2.1×50 mm, 130 Å pore size, 5 µm particle size; Waters 
 Corporation, Milford, MA, USA) using a gradient mobile 
phase consisting of 0.1% formic acid in water (mobile phase 
A) and 0.1% formic acid and 10% isopropanol in acetonitrile 
(mobile phase B) on a Shimadzu LC-20AD (Shimadzu, 
Columbia, MD) liquid chromatography. The flow rate was 
0.33 mL/min and the total run time was 6 minutes. The 
compounds were measured using a Thermo TSQ Ultra Triple 
Quadrupole Mass Spectrometer (Thermo Fisher Scientific, 
Inc, Waltham, MA) equipped with a heated electrospray 
ionization source in the positive ion mode. The discharge 
current was held at 3.7 kV and the vaporizer temperature 
at 225°C. PX, Br-C16-PX, and docetaxel were detected by 
selected-reaction monitoring using the transitions 854 → 
286, 1172 → 604, and 808 → 527, respectively.
PK and biodistribution studies
A549-luc-c8 cells were injected into the left lung parenchyma 
on day 0 as described above. On day 16 post implantation, 
either Taxol at 19 mg/kg or Br-C16-PX NPs at 75 mg/kg of 
the Br-C16-PX conjugate were administered as a single IV 
bolus. Mice were sacrificed at predetermined time points 
(3 mice/time point). Plasma and tissues including tumor-
containing lung, liver, spleen, and kidneys were harvested. 
Discernible lung tumor nodules were dissected for analysis 
when possible. Since pleural effusion was often observed at 
the time of sacrifice, the excess pleural fluid was collected 
when present. Plasma was harvested in sodium fluoride/
potassium oxalate blood collection tubes and tissues were 
homogenized in the presence of 2.5 mg/mL sodium fluoride 
to serve as an esterase inhibitor to prevent ex vivo conver-
sion. The drugs were extracted from the matrix by acetonitrile 
with 0.1% formic acid. The concentrations of PX from Taxol, 
Br-C16-PX from the NPs, and PX converted from Br-C16-PX 
were determined by LC-MS/MS as described above. Non-
compartmental PK analysis was performed using WinNonlin 
version 6.2.0 (Pharsight Corp., Cary, NC, USA). The AUC 
from 0 to 96 hr (AUC
0–96 h





), volume of distribution (V
d
), clearance (CL), 
and mean residence time (MRT) were reported.
statistical analysis
Statistical analysis was performed with Prism (GraphPad Soft-
ware Inc., La Jolla, CA, USA). One-way ANOVA was applied 
for multiple-group comparison, with Tukey’s Multiple Com-
parison Test as a post-test to compare any two groups. Log-
rank Test was performed for survival comparison. Differences 
were considered statistically significant when P0.05.
Results
Optimization and characterization  
of Br-c16-PX NPs
Br-C16-PX was synthesized through the conjugation 
of PX and 2-bromohexadecanoic acid as previously 
reported (Figure 1).9 Br-C16-PX NPs were formulated 
using a microemulsion precursor method with Miglyol 
812 as the oil phase, and Brij 78 and Vitamin E-TPGS 
as surfactants.12,13 To further optimize the Br-C16-PX 
NPs in terms of drug loading, drug entrapment and par-
ticle size, four different formulations (Formulations I–IV) 
of the conjugate were investigated with various concentra-
tions of surfactants and Br-C16-PX (Table 1). Drug entrap-
ment of each formulation was determined using GPC with 
PBS elution. Out of 15 fractions for each formulation, NPs 
of 200 nm size eluted in fractions 3–5 as monitored by light 
scattering intensity and particle size measurement. For For-
mulation I and Formulation II, an additional population of 
smaller particles (∼30 nm) was identified in fractions 6–9. 
These Br-C16-PX-containing smaller particles were likely to 
be micelles generated due to excess amount of surfactants.
With decreasing concentrations of the surfactants, a 
decreasing amount of Br-C16-PX was observed in  fractions 
6–9 of the GPC elution profile, leading to higher drug entrap-































Figure 1 synthesis scheme of Br-c16-PX.
Abbreviation: DMaP, 4-(dimethylamino) pyridine.
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Table 1 Formulation optimization and characterization of Br-c16-PX loaded BTM NPs. Formulation IV was the optimal Br-c16-PX 
NP and was evaluated in subsequent in vitro and in vivo studies








Particle size  
(nm)
% Drug  
in F3–5
I 0.5 2.5 3.7 1.2 184±7 50.87±0.01
II 0.5 2.5 2.0 1.6 188±3 60.64±0.05
III 0.5 2.5 2.0 1.0 170±9 70.00±0.06
IV 1.0 2.5 2.0 1.0 202±3 66.45±0.02
Notes: Miglyol 812 (sasol, Witten, germany); Brij 78 (Uniqema,Wilmington, De, Usa); TPgs (Vitamin e-TPgs; eastman chemicals, Kingsport, TN, Usa).
Abbreviations: Br-c16-PX, 2′-(2-bromohexadecanoyl)-paclitaxel; NPs, nanoparticles; BTM, nanoparticles made from a warm oil-in-water microemulsion precursor with 
Brij 78 and Vitamin e-TPgs as surfactants and Miglyol 812 as the oil phase; F3-5, Fractions 3-5; PX, paclitaxel.
drug entrapment of 0.5 mg/mL Br-C16-PX increased from 
50.87%±0.01% to 70.00%±0.06% from Formulation I to For-
mulation III. In Formulation IV, Br-C16-PX concentration 
was increased to 1.0 mg/mL which yielded a drug entrapment 
of 66.45%±0.02%. Although Formulation IV appeared to 
have a slightly lower drug entrapment than Formulation III, 
it was considered to be the optimal formulation since the drug 
loading capacity was as high as 40% (w/w, drug/oil).
Tubulin polymerization activity  
of Br-c16-PX
The principle of the tubulin polymerization assay is that the 
extent of light being scattered by microtubules is proportional 
to the concentration of microtubule polymer. Under standard 
assay conditions at 37°C, the tubulin polymerization process 
is described by an increasing OD
340 nm 
curve comprised of 
nucleation phase, growth phase, and equilibrium phase. 
The maximum polymerization rate (V
max
) obtained from the 
first derivative of the polymerization curve represents how 
fast the tubulin is polymerized under a certain  condition. 
As shown in Figure 2A, a dose-dependent acceleration 
of tubulin polymerization was observed for Br-C16-PX. 
Br-C16-PX at 10 µM had a V
max
 similar to the negative 
control (20.0±1.4 versus 17.5±2.1 mOD/min). When 
Br-C16-PX concentration was increased to 34 µM, the 
V
max
 (30.5±2.1 mOD/min) was comparable to PX at 10 µM 
(29.0±0.0 mOD/min). It should be noted that the V
max
 was 
reached later for Br-C16-PX (8–9 minutes) in the 60 minute 
time course than PX (0–3 minutes).
cytotoxicity of Br-c16-PX NPs
An in vitro cytotoxicity study of free PX, blank NPs and the 
optimized Br-C16-PX NPs (Formulation IV) was carried 
out in the A549-luc-c8 cell line using the MTT assay. As 
shown in Figure 2B, the IC
50 
of Br-C16-PX NPs was 62.2-
fold higher than free PX (5.3±3.2 nM). This was expected 
and consistent with other reported studies of 2′-PX conju-
gate since the 2′-OH group is crucial to the cytotoxicity 
and tubulin polymerization activity of PX.9,15–17 The blank 
NPs did not show significant cytotoxicity (drug equivalent 
IC
50









































Figure 2 Toxicity study of Br-c16-PX.
Notes: (A) tubulin polymerization activity and Vmax comparison (*P0.05; **P0.01). (B) cytotoxicity study of Br-c16-PX NPs, blank NPs and free PX in a549-luc-c8 cells 
after 48 hr incubation. The Ic50 of blank NPs was calculated at the drug equivalent dose.
Abbreviations: Br-c16-PX, 2′-(2-bromohexadecanoyl)-paclitaxel; PX, paclitaxel; mOD/min, milliOptical Density units per minute; Vmax, maximum polymerization rate; 
NP, nanoparticle; Ic50, concentration that leads to 50% cell survival inhibition.




























Figure 3 In vivo efficacy study in an orthotopic NSCLC model.
Notes: Mice were implanted with 5 million a549-luc-c8 cells in the left lung 
parenchyma on day 0. starting on day 16, Taxol or Br-c16-PX NPs were given 
as weekly intravenous injections for 6 weeks (indicated by the arrows in A). (A) 
survival curve. Survival was significantly improved by Br-C16-PX NPs at 75 mg/kg 
compared to Taxol (P=0.03). (B) and (C), in vivo bioluminescence imaging (color 
scale blue 3.65e6, red 6.68e7), gross lung images, and histology (scale bar, 3 mm) of 
the surviving mice in NP 60 mg/kg group (B) and NP 75 mg/kg group (C) at 154 days 
post tumor implantation. Tumor nodules are indicated by the arrows.
Abbreviations: Nsclc, non-small cell lung cancer; Br-c16-PX, 2′-(2-bromohexa-
decanoyl)-paclitaxel; NPs, nanopar ticles.
In vivo antitumor efficacy studies
The therapeutic efficacy of the optimized Br-C16-PX NPs 
(Formulation IV) was evaluated in the orthotopic NSCLC 
mouse model previously established with A549-luc-c8 cells 
in our laboratory.10 Starting on day 16 post tumor cell 
implantation, Taxol at 19 mg/kg (predetermined MTD) and 
Br-C16-PX NPs at 60 mg/kg (“NP 60 group”) and 75 mg/kg 
of the conjugate (“NP 75 group”) were administered IV with 
the treatment schedule of Q7d ×6. As shown in Figure 3A, the 
control group had a median survival of 31 days, which was 
improved by Taxol treatment to 70 days. A dose response 
was observed for the treatment with Br-C16-PX NPs. Median 
survivals for the NP 60 group and the NP 75 group were 
77 days and 88 days, respectively. The median survival was 
significantly improved by Br-C16-PX NPs at 75 mg/kg com-
pared to the Taxol standard of care at MTD (P=0.03).
The efficacy study was terminated on day 154 post tumor 
cell implantation, when one mouse in the NP 60 group 
and two mice in the NP 75 group were still alive. Stronger 
bioluminescence signals were observed in the lungs of the 
surviving mouse in the NP 60 group (Figure 3B). The two 
mice in the NP 75 group had very low bioluminescence sig-
nals, indicating minimal tumor growth (Figure 3C). Gross 
images and hematoxylin and eosin staining of the lungs 
harvested from the surviving mice agreed with the biolumi-
nescence imaging observations. The lungs of the mice in the 
NP 75 group had either no solid tumor nodule or a very small 
nodule in the left lung. While in the surviving mouse in the 
NP 60 group, an apparent tumor nodule occupied almost the 
entire lobe of the left lung.
PK and biodistribution studies
PK and biodistribution studies of the Br-C16-PX NPs and 
Taxol were carried out in the orthotopic NSCLC model at 
75 mg/kg and 19 mg/kg, respectively. Tumors were distrib-
uted throughout the lung in the form of multiple nodules and 
possibly diffuse cells at the time of tissue collection, which 
made it difficult to dissect all the tumors from the lung in 
a time-efficient manner. Therefore, tumor-containing lungs 
were analyzed as a whole in the PK/biodistribution stud-
ies. However, a number of clearly discernible lung tumors 
were successfully dissected at several time points including 
5 minutes, 15 minutes, 48 hours, 72 hours, and 96 hours. This 
dissection is believed to have minimal impact on quantified 
drug concentrations in the whole tumor-bearing lungs due 
to the small size of the dissected tumors and relatively low 
drug concentration. Excess pleural fluid was generated due to 
tumor growth and was collected for analysis when present.
As shown in Figure 4A and Table 2, plasma concentra-
tion of PX from Taxol decreased rapidly and was below the 
LC-MS/MS quantification range after 8 hours, while the 
concentration of Br-C16-PX was detectable up to 96 hours. 
The clearance and volume of distribution of Br-C16-PX in 
plasma were significantly decreased resulting in increased 
AUC and drug exposure. The clearance of Br-C16-PX from 
the NPs was only 4.3% of the PX clearance from Taxol, and 
the AUC
0–96 h 
was 91.7-fold greater, suggesting prolonged 
systemic circulation of the NPs. The T
1/2 
(27.2 hr versus 
0.8 hr) and MRT (14.5 hr versus 0.7 hr) of PX converted from 
Br-C16-PX were much longer compared to Taxol, indicating 
sustained conversion of PX from the Br-C16-PX NPs.
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Figure 4 Pharmacokinetic and biodistribution studies in an orthotopic Nsclc model (3 mice per time point).
Notes: (A) and (B), PK profile of Br-C16-PX NPs and Taxol in plasma (A) and tumor-bearing lungs (B). Drug concentrations of PX from Taxol (open circle), Br-c16-PX 
from NPs (triangle) and PX converted from Br-C16-PX NPs (square) were quantified by LC-MS/MS. (C) Biodistribution of Br-c16-PX in plasma, liver, spleen, lung, kidney, 
and pleural fluid at predetermined time points. (D) ratio of converted PX to Br-c16-PX in different tissues. ratio = (molar concentration of PX converted from Br-c16-PX)/
(molar concentration of Br-c16-PX).
Abbreviations: conc, concentration; PK, pharmacokinetic; Br-c16-PX, 2′-(2-bromohexadecanoyl)-paclitaxel; NPs, nanoparticles; lc-Ms/Ms, liquid chromatography-
tandem mass spectrometry (Ms/Ms); PX, paclitaxel; Nsclc, non-small cell lung cancer.
Table 2 summary of important pharmacokinetic parameters of PX from Taxol, converted PX and Br-c16-PX from Br-c16-PX NPs. 
These parameters were calculated from the pharmacokinetic data by non-compartmental analysis
Specimen Parameter Unit PX (Taxol) Br-C16-PX NPs
Br-C16-PX PX (converted)
Plasma aUc0–96 h ng/ml⋅hr 16,681.1 1,530,414.1 2,982.7
aUc48–96 h ng/ml⋅hr N/a 24,249.1 1,545.4
T1/2 hr 0.8 7.9 27.2
MrT hr 0.7 2.2 14.5
cl ml/hr/kg 1,136.9 48.9 23,932.9
Vd ml/kg 1,375.7 557.7 939,305.1
lung aUc0–96 h ng/ml⋅hr 52,478.5 2,601,702.8 57,451.0
aUc48–96 h ng/ml⋅hr 8,825.4 1,508,174.0 23,852.0
T1/2 hr 30.3 80.9 34.4
MrT hr 14.7 42.8 32.2
Abbreviations: Br-c16-PX, 2′-(2-bromohexadecanoyl)-paclitaxel; NPs, nanoparticles; aUc, area under the concentration versus time curve; T1/2, half-life; MrT, mean 
residence time; cl, clearance; Vd, volume of distribution; PX, paclitaxel; hr, hour; N/a, not applicable.
Drug concentrations and PK parameters of the tumor-
bearing lungs are illustrated in Figure 4B and Table 2. 
Br-C16-PX had a 49.6-fold greater AUC
0–96 h
 and longer 
T
1/2 
(80.9 hr versus 30.3 hr) compared to Taxol. The concen-
tration of PX converted from Br-C16-PX NPs reached higher 
numbers than Taxol at 4 hours and remained higher up to 





of PX from the NPs were 1.1-
fold and 2.7-fold higher than Taxol, respectively. The signifi-
cantly increased and prolonged exposures of tumor-bearing 
lungs to both Br-C16-PX and converted PX contributed to 
the superior therapeutic efficacy of the Br-C16-PX NPs over 





Taxol observed in the efficacy studies. The biodistribution of 
Br-C16-PX in different specimens is summarized in  Figure 4C. 
Br-C16-PX was distributed primarily in the plasma from 
5 minutes to 4 hours, and then mainly in the liver and spleen 
after 8 hours. The pegylation with 0.2 mg/mL Brij 700 may not 
be dense enough to shield the NPs from the reticuloendothelial 
(RES) system. Denser pegylation is currently being investi-
gated to further decrease RES uptake and prolong circulation 
and ultimately increase tumor accumulation.
Importantly, the ratio of converted PX over the conju-
gate for the Br-C16-PX NPs was higher in pleural fluid and 
lung tumors compared to other tissues (Figure 4D). PX/Br-
C16-PX from 48 hours to 96 hours was between 0.29 and 
0.45 in dissected lung tumors, and between 1.24 and 2.97 in 
pleural fluid containing pleural tumors, likely indicating 
favorable conversion of the conjugate to PX in these com-
partments. Considering that the tubulin stabilization activity 
and cytotoxicity of the conjugate was lower than PX at the 
same concentration (Figure 2), the higher conversion in tumor 
tissue enhances the in vivo efficacy of the NPs. The higher 
conversion in pleural fluid may provide a better opportunity 
for the converted PX to diffuse into adjacent tumor sites in 
the lung, and enable a therapeutic benefit against pleural 
tumors. On the other hand, minimal conversion in non-tumor 
tissues and organs could help protect healthy tissues from 
systemic toxicity.
Discussion
In current studies, a lipophilic PX conjugate 2′-(2-
bromohexadecanoyl)-paclitaxel (Br-C16-PX) was synthe-
sized and incorporated into lipid-based NPs. The conjugate 
was evaluated for tubulin stabilization activity and cyto-
toxicity. In the tubulin polymerization assay (Figure 2), 
Br-C16-PX at 10 µM exhibited a lower tubulin stabilization 
effect compared to PX at the same concentration presumably 
due to the modification of the 2′-OH group.15–17 However, 
when the Br-C16-PX was increased to 34 µM, accelerated 
microtubule polymerization was observed similar to PX 
at 10 µM, indicating a tubulin stabilization effect of the 
conjugate.
Similar to compromised tubulin polymerization activity, 
free Br-C16-PX was expected to be less cytotoxic than the 
parent drug PX due to the conjugation of the 2′ hydroxyl 
group.15 Due to increased lipophilicity of Br-C16-PX 
after conjugation of the 16-carbon chain, its solubility in 
DMSO was not high enough to enable the IC
50
 analysis of 
free Br-C16-PX via MTT assay. Cytotoxicity of the Br-
C16-PX NPs was investigated instead and results showed 
an IC
50
 that was 62.2-fold higher than free PX, which is 
consistent with other reported 2′-PX conjugates.9,15–17
The lipid-based NPs with Br-C16-PX were optimized 
to have a drug loading as high as 40% (w/w, drug/oil) and a 
drug entrapment of 66.45%±0.02%. In contrast, previously 
reported PX BTM NPs and C22-PX BTM NPs had a drug 
loading of only 7.5% and 7.7% by weight, respectively,18,19 
likely due to relatively low affinity of PX to the Miglyol oil 
core in the PX BTM NPs or excess amount of surfactant in the 
C22-PX BTM NPs. From Formulation I to Formulation IV 
(Table I), Brij 78 concentration was decreased from 
3.7 mg/mL to 2.0 mg/mL and Vitamin E-TPGS concen-
tration was decreased from 1.2 mg/mL to 1.0 mg/mL. 
Higher drug entrapment was achieved with decreasing con-
centrations of the surfactants.
The optimized Br-C16-PX NPs (Formulation IV) were 
evaluated for the treatment of NSCLC. About 15% of lung 
cancer cases are diagnosed at early stage with a 5 year 
survival of 52.6%. For the majority of patients who are 
diagnosed with distant tumors, the 5 year survival rate is 
only 3.5%.11 More efficacious therapy options for advanced 
lung cancer are in great demand. However, treatments are 
started relatively early in the majority of preclinical studies 
in orthotopic lung cancer mouse models. Bao et al treated 
orthotopic A549 tumor with a heat shock protein 90 inhibitor 
starting on day 4 after tumor implantation, which is 10.5% of 
the 38 day median survival in control group.20 Jin et al started 
the treatment of orthotopic H460 tumor on day 10, which is 
23.5% of the 42.5 day median survival.21 Furthermore, treat-
ment of advanced lung tumors is more challenging due to the 
well-developed and likely more aggressive primary tumor 
as well as potential metastasis. Doki et al treated orthotopic 
Lewis lung carcinoma with cisplatin either starting on day 1 
or day 10, which is 4.8% and 47.6% of the 21 day median 
survival, respectively.22 Cisplatin suppressed primary lung 
tumor growth and lymph node metastasis only in the day 1 
treatment group, and failed to show any significant therapeu-
tic effect in the day 10 treatment group.
In our in vivo efficacy studies in the orthotopic NSCLC 
mouse model, the Br-C16-PX NP treatment was started on 
day 16 post tumor cell implantation (51.5% of the 31 day 
median survival) instead of day 5 in the previously pub-
lished studies with Br-C16-DX NPs10 to mimic the therapy 
of advanced NSCLC. The MTD of the Br-C16-PX NPs in 
non-tumor-bearing mice in the previously published studies 
was determined to be between 90 mg/kg and 120 mg/kg of 
the conjugate. However, the chemotherapeutic tolerance of 
orthotopic lung tumor-bearing mice was decreased due to 




Paclitaxel conjugate NPs for lung cancer treatment
compromised lung function and was related to the extent of 
tumor progression. Therefore, the drug dose in the current 
studies was decreased proportionately based on the MTD 
in healthy mice. Two doses (60 mg/kg and 75 mg/kg) of 
the Br-C16-PX NPs were chosen and evaluated for in vivo 
efficacy. The median survival was slightly improved by the 
Br-C16-PX NPs at the lower dose and further improved 
at the high dose (P=0.03) compared to Taxol standard of 
care (Figure 3). After the treatment was started in the NP 
75 group, a minor weight loss was observed from which the 
mice recovered quickly, so it is believed that 75 mg/kg is very 
close to the actual MTD in the tumor-bearing mice.
There are several possible reasons for the superior thera-
peutic efficacy of the Br-C16-PX NPs over Taxol. First, the 
MTD of the NPs was greatly increased (4-fold higher than 
Taxol) likely due to the fact that the NP formulation consists 
of generally regarded as safe excipients instead of toxic Cre-
mophor and ethanol in Taxol, allowing for higher delivered 
dose. Moreover, the decreased clearance and prolonged 
circulation provided more time for the NPs to circulate and 
accumulate into the orthotopic tumors via the enhanced per-
meability and retention (EPR) effect. Indeed, in the PK studies 
(Figure 4 and Table 2), the plasma T
1/2 
of Br-C16-PX from the 
NPs was increased to 7.9 hours compared to PX from Taxol 
at 0.8 hours. AUC
0–96 h 
of Br-C16-PX in plasma and tumor-
bearing lung was 91.6-fold and 49.6-fold higher than Taxol, 
respectively. In tumor-bearing lungs, the MRT of converted 





of converted PX from the NPs were 
1.1-fold and 2.7-fold greater than Taxol, respectively.
In addition to increased drug exposure, higher ratio of 
converted PX/Br-C16-PX was observed primarily in tumor 
(ratio up to 0.45) and pleural fluid (ratio up to 2.97). The 
higher ratio likely indicated favorable conversion of the 
conjugate to PX in these compartments which would enable 
more effective tumor treatment. The improved conversion 
was attributable to the electron-withdrawing Br group at the 
2-position of the 16-carbon chain. The selective conversion 
in pleural fluid and tumor was likely caused by tissue-specific 
enzymatic activity and/or pH environment. Shaffer et al found 
that the metabolism of a paclitaxel poliglumex is at least par-
tially mediated by the lysosomal enzyme cathepsin B, whose 
expression is up-regulated in many tumor types including 
lung tumors.23 Additionally, lower pH in the tumor interstitial 
fluid and also late endosomes and lysosomes could facilitate 
chemical hydrolysis of the Br-C16-PX conjugate especially 
with the presence of Br.24,25 Pleural effusion generated in the 
orthotopic mouse model was a thick fluid containing tumor 
cells, red blood cells, and some immune cells. The higher ratio 
of converted PX/Br-C16-PX in pleural fluid as compared to 
lung tumors may be caused by sequestration of the NPs in 
pleural cavity, and the absence of tumor stroma in the fluid 
environment thus easier access of the NPs to pleural tumors 
compared to solid lung tumors.
Conclusion
In the current studies, lipid-based NPs with Br-C16-PX were 
developed and evaluated for the treatment of NSCLC. The 
optimized Br-C16-PX NPs had a drug entrapment of 66.45% 
and exhibited moderate cytotoxicity in A549-luc-c8 cells. 
The Br-C16-PX NPs had superior antitumor efficacy as 
compared to Taxol for the treatment of advanced NSCLC in 
a novel orthotopic mouse model (P=0.03). Prolonged circu-
lation, enhanced drug exposure, and selective conversion of 
Br-C16-PX to release PX contributed to the improved thera-
peutic efficacy of the Br-C16-PX NPs. Denser pegylation 
and CD44 targeted NPs are under investigation to further 
enhance the therapeutic index of the developed system.8
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